title: Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.
authors.affiliation: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: F
authors.initials: F
authors.lastname: Ravandi
authors.affiliation: Service des Maladies du Sang, Centre François Magendie, Hôpital du Haut-Lévèque, Pessac, France.
authors.forename: A
authors.initials: A
authors.lastname: Pigneux
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: DeAngelo
authors.affiliation: Department of Adult Hematology, Hôpital Saint Louis, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Raffoux
authors.affiliation: Department of Hematology, Hôpital Hotel Dieu, Nantes, France.
authors.forename: J
authors.initials: J
authors.lastname: Delaunay
authors.affiliation: Department of Hematology, Hôpital Edouard Herriot, Lyon, France.
authors.forename: X
authors.initials: X
authors.lastname: Thomas
authors.affiliation: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kadia
authors.affiliation: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.affiliation: Clinical Biomarkers, Merck KGaA, Darmstadt, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Scheuenpflug
authors.affiliation: Clinical Oncology, Early Development, EMD Serono, Billerica, MA, USA.
authors.forename: C
authors.initials: C
authors.lastname: Zhao
authors.affiliation: Clinical Oncology, Early Development, EMD Serono, Billerica, MA, USA.
authors.forename: W
authors.initials: W
authors.lastname: Guo
authors.affiliation: Global Biostatistics, Hematologic Cancer and BMT, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD, USA.
authors.forename: B D
authors.initials: BD
authors.lastname: Smith
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C550600:N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide; D009536:Niacinamide